Incipient tuberculosis: a comprehensive overview.
Incipient tuberculosis
Tuberculosis
Tuberculosis infection
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
27
02
2024
accepted:
13
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
In the context of the evolving global health landscape shaped by the COVID-19 pandemic, tuberculosis (TB) is gaining renewed attention as a reemerging threat even in low-endemic countries. Immunological tests such as the tuberculin skin test (TST) and interferon-gamma release assay (IGRA) are pivotal in identifying tuberculosis infection (TBI). However, their inability to distinguish between past and ongoing infection poses a diagnostic challenge, possibly leading to the unnecessary treatment of a significant portion of the population with potential side effects. This review delves into the concept of incipient tuberculosis (ITB), a dynamic, presymptomatic stage characterized by heightened Mycobacterium tuberculosis complex (MTC) metabolic activity and replication that result in minimal radiological changes, signifying a transitional state between TBI and TB. Key focus areas include epidemiological factors, underlying pathogenesis, imaging findings, and the ongoing challenges in the identification of individuals with ITB through the development of new biomarkers and the use of whole-genome sequencing-based analyses to implement early treatment strategies.
Identifiants
pubmed: 38589748
doi: 10.1007/s15010-024-02239-4
pii: 10.1007/s15010-024-02239-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Rotundo S, Morrone HL, Gallo L, Dodaro S, D’Aleo F, Minchella P, et al. Are we doing enough for controlling tuberculosis and multi-drug resistance in an epicenter of the current migration emergency (Calabria Region, Southern Italy)? Infection. 2023. https://doi.org/10.1007/s15010-023-02106-8 .
doi: 10.1007/s15010-023-02106-8
pubmed: 37838640
Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis. 2011;204:S1179–86. https://doi.org/10.1093/infdis/jir451 .
doi: 10.1093/infdis/jir451
pubmed: 21996700
pmcid: 3192549
Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018. https://doi.org/10.1128/CMR.00021-18 .
doi: 10.1128/CMR.00021-18
pubmed: 30021818
pmcid: 6148193
Verma R, Swift BMC, Handley-Hartill W, Lee JK, Woltmann G, Rees CED, et al. A novel, high-sensitivity, bacteriophage-based assay identifies low-level mycobacterium tuberculosis bacteremia in immunocompetent patients with active and incipient tuberculosis. Clin Infect Dis. 2020;70:933–6. https://doi.org/10.1093/cid/ciz548 .
doi: 10.1093/cid/ciz548
pubmed: 31233122
Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol. 2012;12:581–91. https://doi.org/10.1038/nri3259 .
doi: 10.1038/nri3259
pubmed: 22790178
Behr MA, Kaufmann E, Duffin J, Edelstein PH, Ramakrishnan L. Latent tuberculosis: two centuries of confusion. Am J Respir Crit Care Med. 2021;204:142–8. https://doi.org/10.1164/rccm.202011-4239PP .
doi: 10.1164/rccm.202011-4239PP
pubmed: 33761302
pmcid: 8650795
WHO operational handbook on tuberculosis. Module 1: prevention - infection prevention and control. Geneva: World Health Organization; 2023.
Lin CK, Fan HJ, Yu KL, Chang LY, Wen YF, Keng LT, et al. Effectiveness of endobronchial ultrasound-guided transbronchial biopsy combined with tissue culture for the diagnosis of sputum smear-negative pulmonary tuberculosis. Front Microbiol. 2022;13:847479. https://doi.org/10.3389/fmicb.2022.847479 .
doi: 10.3389/fmicb.2022.847479
pubmed: 35547142
pmcid: 9081838
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69:1–11. https://doi.org/10.15585/mmwr.rr6901a1 .
doi: 10.15585/mmwr.rr6901a1
pubmed: 32053584
pmcid: 7041302
Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2023;11:367–79. https://doi.org/10.1016/S2213-2600(23)00097-8 .
doi: 10.1016/S2213-2600(23)00097-8
pubmed: 36966795
National Tuberculosis Controllers A, Centers for Disease C, Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54:1–47.
Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10. https://doi.org/10.1038/emi.2016.10 .
doi: 10.1038/emi.2016.10
pubmed: 26839146
pmcid: 4777925
Haley CA. Treatment of latent tuberculosis infection. Microbiol Spectr. 2017. https://doi.org/10.1128/microbiolspec.TNMI7-0039-2016 .
doi: 10.1128/microbiolspec.TNMI7-0039-2016
pubmed: 28409555
Katsenos S, Nikolopoulou M, Konstantinidis AK, Gartzonika C, Gogali A, Margelis I, et al. Interferon-gamma release assay clarifies the effect of BACILLE CALMETTE-Guerin vaccination in Greek army recruits. Int J Tuberc Lung Dis. 2010;14:545–50.
pubmed: 20392346
To KW, Kam KM, Chan DPC, Yip WH, Chan KP, Lo R, et al. Utility of GeneXpert in analysis of bronchoalveolar lavage samples from patients with suspected tuberculosis in an intermediate-burden setting. J Infect. 2018;77:296–301. https://doi.org/10.1016/j.jinf.2018.06.011 .
doi: 10.1016/j.jinf.2018.06.011
pubmed: 29964143
Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis. 2015;32:87–93. https://doi.org/10.1016/j.ijid.2014.12.007 .
doi: 10.1016/j.ijid.2014.12.007
pubmed: 25809762
Kim JW, Bowman K, Nazareth J, Lee J, Woltmann G, Verma R, et al. PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study. Lancet Microbe. 2024. https://doi.org/10.1016/S2666-5247(23)00289-6 .
doi: 10.1016/S2666-5247(23)00289-6
pubmed: 38310908
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387:2312–22. https://doi.org/10.1016/S0140-6736(15)01316-1 .
doi: 10.1016/S0140-6736(15)01316-1
pubmed: 27017310
pmcid: 5392204
Suliman S, Thompson EG, Sutherland J, Weiner J 3rd, Ota MOC, Shankar S, et al. Four-Gene pan-African blood signature predicts progression to tuberculosis. Am J Respir Crit Care Med. 2018;197:1198–208. https://doi.org/10.1164/rccm.201711-2340OC .
doi: 10.1164/rccm.201711-2340OC
pubmed: 29624071
pmcid: 6019933
Singhania A, Verma R, Graham CM, Lee J, Tran T, Richardson M, et al. A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat Commun. 2018;9:2308. https://doi.org/10.1038/s41467-018-04579-w .
doi: 10.1038/s41467-018-04579-w
pubmed: 29921861
pmcid: 6008327
Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738. https://doi.org/10.1136/bmj.k2738 .
doi: 10.1136/bmj.k2738
pubmed: 30139910
pmcid: 6105930
Yoon SH, Goo JM, Yim JJ, Yoshiyama T, Flynn JL. CT and (18)F-FDG PET abnormalities in contacts with recent tuberculosis infections but negative chest X-ray. Insights Imaging. 2022;13:112. https://doi.org/10.1186/s13244-022-01255-y .
doi: 10.1186/s13244-022-01255-y
pubmed: 35796839
pmcid: 9261169
Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging. 2008;35:808–14. https://doi.org/10.1007/s00259-007-0585-0 .
doi: 10.1007/s00259-007-0585-0
pubmed: 18097664
Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271–86. https://doi.org/10.1146/annurev-publhealth-031912-114431 .
doi: 10.1146/annurev-publhealth-031912-114431
pubmed: 23244049
Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and mycobacterium tuberculosis co-infection. Nat Rev Microbiol. 2018;16:80–90. https://doi.org/10.1038/nrmicro.2017.128 .
doi: 10.1038/nrmicro.2017.128
pubmed: 29109555
Bottai D, Frigui W, Sayes F, Di Luca M, Spadoni D, Pawlik A, et al. TbD1 deletion as a driver of the evolutionary success of modern epidemic mycobacterium tuberculosis lineages. Nat Commun. 2020;11:684. https://doi.org/10.1038/s41467-020-14508-5 .
doi: 10.1038/s41467-020-14508-5
pubmed: 32019932
pmcid: 7000671
Ashenafi S, Aderaye G, Bekele A, Zewdie M, Aseffa G, Hoang AT, et al. Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3. Clin Immunol. 2014;151:84–99. https://doi.org/10.1016/j.clim.2014.01.010 .
doi: 10.1016/j.clim.2014.01.010
pubmed: 24584041
Ndlovu H, Marakalala MJ. Granulomas and inflammation: host-directed therapies for tuberculosis. Front Immunol. 2016;7:434. https://doi.org/10.3389/fimmu.2016.00434 .
doi: 10.3389/fimmu.2016.00434
pubmed: 27822210
pmcid: 5075764
Cross GB, J OD, Chang C, Kelleher AD, Paton NI,. Does PET-CT have a role in the evaluation of TB treatment in Phase II Clinical Trials? J Infect Dis. 2023. https://doi.org/10.1093/infdis/jiad425 .
doi: 10.1093/infdis/jiad425
pubmed: 37849403
pmcid: 10651188
Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission and computed tomography. Nat Med. 2016;22:1090–3. https://doi.org/10.1038/nm.4161 .
doi: 10.1038/nm.4161
pubmed: 27595321
pmcid: 5055809
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021;21:354–65. https://doi.org/10.1016/S1473-3099(20)30914-2 .
doi: 10.1016/S1473-3099(20)30914-2
pubmed: 33508224
pmcid: 7907670
Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis. 2010;14:1112–9.
pubmed: 20819255
Winje BA, White R, Syre H, Skutlaberg DH, Oftung F, Mengshoel AT, et al. Stratification by interferon-gamma release assay level predicts risk of incident TB. Thorax. 2018. https://doi.org/10.1136/thoraxjnl-2017-211147 .
doi: 10.1136/thoraxjnl-2017-211147
pubmed: 30355641
Roe J, Venturini C, Gupta RK, Gurry C, Chain BM, Sun Y, et al. Blood transcriptomic stratification of short-term risk in contacts of tuberculosis. Clin Infect Dis. 2020;70:731–7. https://doi.org/10.1093/cid/ciz252 .
doi: 10.1093/cid/ciz252
pubmed: 30919880
Xiao YX, Liu KH, Lin WH, Chan TH, Jou R. Whole-genome sequencing-based analyses of drug-resistant mycobacterium tuberculosis from Taiwan. Sci Rep. 2023;13:2540. https://doi.org/10.1038/s41598-023-29652-3 .
doi: 10.1038/s41598-023-29652-3
pubmed: 36781938
pmcid: 9925824